Abstract Search

ea0090p410 | Pituitary and Neuroendocrinology | ECE2023

Impact of Surgery or Medical Treatment with the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients with Cushing Syndrome

Simeoli Chiara , Di Paola Nicola , Stigliano Antonio , Lardo Pina , Kearney Tara , Mezosi Emese , Ghigo Ezio , Giordano Roberta , Mariash Cary N. , Donegan Diane , Feelders Richard , Hand Austin , Moraitis Andreas G. , Pivonello Rosario

In patients with Cushing syndrome (CS), hypercoagulability represents a significant concern, leading to elevated risk for thrombotic events. After curative surgery, hypercoagulability persists for several months; CS treatment guidelines recommend anticoagulation therapy for ≤ 3 months. In patients with Cushing disease, hemostatic parameters may even worsen after surgery, independent of surgical outcome; improvements begin ~3 months after successful surgery (Casonato ...

1 shares

Endocrine Abstracts

Impact of Surgery or Medical Treatment with the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients with Cushing Syndrome

BiosciAbstracts